Corcept Therapeutics Incorporated (CORT)

Corcept Therapeutics Incorporated is a NASDAQ-listed common stock issuer in the healthcare sector focused on biopharmaceutical research and development. The company develops medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. Its marketed product is Korlym, an oral treatment for hyperglycemia associated with hypercortisolism in adults with endogenous Cushing’s syndrome who also have type 2 diabetes mellitus or glucose intolerance and are not candidates for, or have failed, surgery. Corcept is also advancing relacorilant, a selective cortisol modulator for hypercortisolism, along with miricorilant, which is in Phase 1b testing for metabolic dysfunction-associated steatohepatitis. The company’s portfolio also includes other proprietary selective cortisol modulators under development, including nenocorilant and dazucorilant, for Lou Gehrig’s disease. Corcept Therapeutics was incorporated in 1998 and is headquartered in Redwood City, California.

Jump directly to the stock analysis sections supported by the latest available data.